Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
PAVmed ( (PAVM) ) just unveiled an update.
On May 15, 2025, PAVmed Inc. provided a business update and reported its first-quarter financial results for 2025. Lucid Diagnostics secured capital to extend its runway beyond key reimbursement milestones and reported $0.8 million in revenue from its EsoGuard Esophageal DNA Test. Veris Health resumed development of its implantable physiological monitor and is set to launch a commercial partnership with a major cancer center. PAVmed is actively seeking to expand into the biopharma sector, evaluating clinical and late preclinical-stage assets. Financially, PAVmed ended the first quarter with over $40 million in pro forma cash, and its operating expenses were approximately $5.5 million, resulting in a GAAP net income of $17.7 million.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Underperform.
PAVmed’s overall score is primarily impacted by its weak financial performance, with ongoing losses and high leverage posing significant risks. The earnings call provided some positive developments in subsidiary growth and strategic initiatives, but these are offset by financial restructuring challenges and the need for external financing. Technical analysis shows short-term momentum but lacks strong long-term signals, while valuation indicates overvaluation due to negative earnings.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. The company has subsidiaries including Lucid Diagnostics Inc., which focuses on diagnostic solutions, and Veris Health Inc., which operates in digital health. PAVmed is expanding its portfolio into the biopharma sector, leveraging its infrastructure to explore clinical and late preclinical-stage assets.
Average Trading Volume: 155,976
Technical Sentiment Signal: Sell
Current Market Cap: $12.56M
Learn more about PAVM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue